Amazon Biotech Announces Appointment of Dr. Michael Silver as New Scientific Director

Market Wire, May, 2008

Amazon Biotech, Inc. (OTCBB: AMZO) (FRANKFURT: B2DA.F) announced that Dr. Michael Silver has been appointed as the company's new Scientific Director.

Dr. Silver has over 15 years of experience in the biotechnology, pharmaceutical and medical device industries serving as Director of Business Development and Senior Scientist at Bio-Imaging Technologies, Inc., as Director of Scientific Services at Synarc, Inc. and as Vice President, Clinical Research at DOBI Medical International, Inc., in charge of the development of their breast cancer diagnostics device. Dr. Silver has eight years' experience implementing imaging biomarkers in clinical trials for oncology, central nervous system (CNS), rheumatology, and cardiovascular therapeutics. He received his Bachelor of Science degree in Physics with honors from Lafayette College. His Master's in Biophysics and his Ph.D. in Electrical Engineering and Computer Science were earned at Johns Hopkins University. Dr. Silver has co-authored over 40 peer-reviewed publications and presentations, and is currently a Research Assistant Professor (part-time) of Psychiatry at NYU Medical School.

Mr. Eliyahu Tolchinsky, Amazon's CEO, said, "We look forward to utilizing Dr. Silver's professional experience and expertise in advancing Amazon's Research and Development plans."

Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future with the goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials or enter the FDA Fast Track program to reach the marketplace. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com/ .

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.

Contact: LC Group Rick Lutz (404) 261-1196